EXPRS2.ST
ExpreS2ion Biotech Holding AB (publ) [EXPRS2.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
EXPRS2.ST Stock Summary
Top 10 Correlated Stocks
EXPRS2.ST
In the News
EXPRS2.ST Financial details
Company Rating
Neutral
Market Cap
112.58M
Income
-95.99M
Revenue
5.94M
Book val./share
-
Cash/share
1.12
Dividend
-
Dividend %
-
Employees
20
Optionable
No
Shortable
Yes
Earnings
08 Feb 2024
P/E
-1.45
Forward P/E
-
PEG
0.45
P/S
27.7
P/B
2.29
P/C
2.28
P/FCF
-1.5
Quick Ratio
4.04
Current Ratio
5
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.12
EPS next Y
-
EPS next Q
-
EPS this Y
-33.76%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
15.09%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-20.45%
-
-
-
-
SMA20
-3.72%
SMA50
-30.24%
SMA100
124.04%
Inst Own
-
Inst Trans
-
ROA
-124%
ROE
-139%
ROC
-1.67%
Gross Margin
36%
Oper. Margin
-2003%
Profit Margin
-1833%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.713-6.46
52W High
-
52W Low
-
RSI
53.16
Rel Volume
0.73
Avg Volume
126.68K
Volume
93.02K
Perf Week
21.43%
Perf Month
-4.14%
Perf Quarter
181.77%
Perf Half Y
88.89%
-
-
-
-
Beta
1.762
-
-
Volatility
0.26%, 0.16%
Prev Close
-7.27%
Price
2.55
Change
-8.93%
EXPRS2.ST Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.85 | 0.27 | 0.38 | 0.13 | 0 | |
| Net income per share | -1.03 | -1.66 | -1.36 | -3.14 | -2.08 | |
| Operating cash flow per share | -0.78 | -0.95 | -1.42 | -2.64 | 0 | |
| Free cash flow per share | -0.83 | -1 | -1.44 | -2.65 | 0 | |
| Cash per share | 0.28 | 5.54 | 4.31 | 2.9 | 1.25 | |
| Book value per share | -0.07 | 4.94 | 4.35 | 2.74 | 0 | |
| Tangible book value per share | -0.46 | 4.73 | 4.25 | 2.66 | 1.61 | |
| Share holders equity per share | -0.07 | 4.94 | 4.35 | 2.74 | 0 | |
| Interest debt per share | 0.15 | 0.31 | 0.07 | 0.07 | 0 | |
| Market cap | 62.83M | 208.48M | 1.19B | 623.82M | 97.37M | |
| Enterprise value | 58.91M | 104.03M | 1.15B | 514.7M | 39.78M | |
| P/E ratio | -3.76 | -6.57 | -26.99 | -5.26 | -1.01 | |
| Price to sales ratio | 4.54 | 39.64 | 96.9 | 122.65 | 0 | |
| POCF ratio | -4.95 | -11.47 | -25.97 | -6.26 | 0 | |
| PFCF ratio | -4.7 | -10.94 | -25.57 | -6.24 | 0 | |
| P/B Ratio | -58.23 | 2.21 | 8.45 | 6.04 | 0 | |
| PTB ratio | -58.23 | 2.21 | 8.45 | 6.04 | 0 | |
| EV to sales | 4.26 | 19.78 | 94.02 | 101.2 | 0 | |
| Enterprise value over EBITDA | -3.87 | -3.65 | -25.17 | -4.13 | 2.29 | |
| EV to operating cash flow | -4.64 | -5.72 | -25.2 | -5.17 | 0 | |
| EV to free cash flow | -4.41 | -5.46 | -24.81 | -5.15 | 0 | |
| Earnings yield | -0.27 | -0.15 | -0.04 | -0.19 | -0.99 | |
| Free cash flow yield | -0.21 | -0.09 | -0.04 | -0.16 | 0 | |
| Debt to equity | -1.38 | 0.03 | 0.02 | 0.02 | 0 | |
| Debt to assets | 0.08 | 0.02 | 0.01 | 0.01 | 0 | |
| Net debt to EBITDA | 0.26 | 3.67 | 0.77 | 0.88 | -3.32 | |
| Current ratio | 0.83 | 6.18 | 19.63 | 4.2 | 0 | |
| Interest coverage | -16.78 | -8.83 | 0 | -146.51 | 0 | |
| Income quality | 0.7 | 0.58 | 0.94 | 0.78 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.62 | 4.08 | 0.29 | 0 | 0 | |
| Research and developement to revenue | 0 | 0.04 | 0.8 | 14.02 | 0 | |
| Intangibles to total assets | 0.34 | 0.03 | 0.02 | 0.02 | 0 | |
| Capex to operating cash flow | 0.05 | 0.05 | 0.02 | 0 | 0 | |
| Capex to revenue | -0.05 | -0.17 | -0.06 | -0.08 | 0 | |
| Capex to depreciation | -0.24 | -0.3 | -0.4 | -0.31 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.24 | 13.58 | 11.55 | 13.91 | 0 | |
| ROIC | -10.1 | -0.29 | -0.31 | -1.14 | 0 | |
| Return on tangible assets | -1.36 | -0.28 | -0.3 | -0.88 | -1.29 | |
| Graham Net | -0.74 | 4.46 | 4.11 | 2.21 | 1.25 | |
| Working capital | -2.08M | 94.25M | 139M | 100.52M | 0 | |
| Tangible asset value | -7.5M | 90.45M | 137.2M | 100.37M | 74.26M | |
| Net current asset value | -9.65M | 88.15M | 134.85M | 97.91M | 0 | |
| Invested capital | -1.38 | 0.03 | 0.02 | 0.02 | 0 | |
| Average receivables | 2.17M | 4.73M | 6.1M | 8.95M | 5.4M | |
| Average payables | 844.5K | 1.58M | 1.88M | 6.92M | 6.08M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 114.76 | 354.24 | 211.98 | 774.64 | 0 | |
| Days payables outstanding | 116.19 | 124.3 | 81.86 | 872.95 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 3.18 | 1.03 | 1.72 | 0.47 | 0 | |
| Payables turnover | 3.14 | 2.94 | 4.46 | 0.42 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 15.48 | -0.34 | -0.31 | -1.15 | 0 | |
| Capex per share | -0.04 | -0.05 | -0.02 | -0.01 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.02 | 0.07 | 0.04 | 0.03 | 0 | |
| Net income per share | -1.2 | -0.7 | -0.63 | -0.44 | -0.35 | |
| Operating cash flow per share | -0.98 | -1.05 | -0.72 | -0.25 | 0 | |
| Free cash flow per share | -0.98 | -1.08 | -0.74 | -0.25 | 0 | |
| Cash per share | 2.71 | 1.87 | 1.82 | 1.52 | 1.12 | |
| Book value per share | 2.56 | 2.11 | 2.12 | 1.61 | 0 | |
| Tangible book value per share | 2.48 | 2.04 | 2.06 | 1.56 | 1.44 | |
| Share holders equity per share | 2.56 | 2.11 | 2.12 | 1.61 | 0 | |
| Interest debt per share | 0.05 | 0.06 | 0.04 | 0.07 | 0 | |
| Market cap | 668.45M | 199.13M | 181.14M | 69.45M | 108.46M | |
| Enterprise value | 559.32M | 129.16M | 94.95M | -5.65M | 50.87M | |
| P/E ratio | -3.44 | -1.89 | -1.51 | -0.8 | -1.52 | |
| Price to sales ratio | 687.7 | 77.6 | 94.29 | 47.76 | 0 | |
| POCF ratio | -16.95 | -5.04 | -5.31 | -5.66 | 0 | |
| PFCF ratio | -16.87 | -4.89 | -5.2 | -5.65 | 0 | |
| P/B Ratio | 6.47 | 2.51 | 1.8 | 0.87 | 0 | |
| PTB ratio | 6.47 | 2.51 | 1.8 | 0.87 | 0 | |
| EV to sales | 575.44 | 50.34 | 49.43 | -3.89 | 0 | |
| Enterprise value over EBITDA | -10.57 | -4.36 | -2.89 | 0.26 | 13.45 | |
| EV to operating cash flow | -14.18 | -3.27 | -2.78 | 0.46 | 0 | |
| EV to free cash flow | -14.12 | -3.17 | -2.72 | 0.46 | 0 | |
| Earnings yield | -0.07 | -0.13 | -0.17 | -0.31 | -0.16 | |
| Free cash flow yield | -0.06 | -0.2 | -0.19 | -0.18 | 0 | |
| Debt to equity | 0.02 | 0.03 | 0.02 | 0.03 | 0 | |
| Debt to assets | 0.01 | 0.02 | 0.02 | 0.02 | 0 | |
| Net debt to EBITDA | 2.06 | 2.36 | 2.63 | 3.46 | -15.23 | |
| Current ratio | 4.2 | 4.72 | 9.21 | 5 | 0 | |
| Interest coverage | -631.93 | -96.37 | 0 | -17.99 | 0 | |
| Income quality | 0.74 | 1.32 | 1.03 | 0.55 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 39.11 | 5.61 | 9.18 | 6.86 | 0 | |
| Intangibles to total assets | 0.02 | 0.03 | 0.02 | 0.03 | 0 | |
| Capex to operating cash flow | 0 | 0.03 | 0.02 | 0 | 0 | |
| Capex to revenue | -0.2 | -0.48 | -0.39 | -0.02 | 0 | |
| Capex to depreciation | -0.71 | -3.72 | -1.73 | -0.06 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 8.31 | 5.77 | 5.5 | 4 | 0 | |
| ROIC | -0.46 | -0.31 | -0.3 | -0.25 | 0 | |
| Return on tangible assets | -0.36 | -0.26 | -0.27 | -0.22 | -0.24 | |
| Graham Net | 2.06 | 1.73 | 1.63 | 1.36 | 1.12 | |
| Working capital | 100.52M | 76.11M | 96.94M | 76.29M | 0 | |
| Tangible asset value | 100.37M | 76.6M | 97.81M | 77.4M | 74.26M | |
| Net current asset value | 97.91M | 72.93M | 93.53M | 73.53M | 0 | |
| Invested capital | 0.02 | 0.03 | 0.02 | 0.03 | 0 | |
| Average receivables | 13.17M | 17.7M | 22.53M | 19.32M | 9.1M | |
| Average payables | 12.57M | 11.98M | 7.07M | 2.78M | 1.62M | |
| Average inventory | -7.77M | 0.5 | -9.52M | -9.52M | 0 | |
| Days sales outstanding | 999.44 | 863.17 | 957.91 | 1.13K | 0 | |
| Days payables outstanding | 822.32 | 791.05 | 213.48 | 367.51 | 0 | |
| Days of inventory on hand | 0 | 0 | -1.74K | 0 | 0 | |
| Receivables turnover | 0.09 | 0.1 | 0.09 | 0.08 | 0 | |
| Payables turnover | 0.11 | 0.11 | 0.42 | 0.24 | 0 | |
| Inventory turnover | 0 | 1.34M | -0.05 | 0 | 0 | |
| ROE | -0.47 | -0.33 | -0.3 | -0.27 | 0 | |
| Capex per share | 0 | -0.03 | -0.02 | 0 | 0 |
EXPRS2.ST Frequently Asked Questions
What is ExpreS2ion Biotech Holding AB (publ) stock symbol ?
ExpreS2ion Biotech Holding AB (publ) is a DK stock and trading under the symbol EXPRS2.ST
What is ExpreS2ion Biotech Holding AB (publ) stock quote today ?
ExpreS2ion Biotech Holding AB (publ) stock price is $2.55 today.
Is ExpreS2ion Biotech Holding AB (publ) stock public?
Yes, ExpreS2ion Biotech Holding AB (publ) is a publicly traded company.
Company Profile
- Volume Average 126.68K
- Market Capitalization 112.58M
- Employee 20
- CEO Mr. Bent U. Frandsen MSc
- Headquarters Horsholm,DK
- IPO Date 2016-07-29
-
Website
https://www.expres2ionbio.com 
ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase II clinical trial. It also develops influenza and breast cancer vaccine, which is in Phase II clinical trial, as well as develops malaria vaccine. In addition, the company licenses its ExpreS2 platform to research institutes and pharmaceutical companies. ExpreS2ion Biotech Holding AB (publ) was founded in 2015 is based in Horsholm, Denmark.
